Holen Sie sich die Stockscreener-App
15.24
5.25%
0.76
Handel nachbörslich:
15.24
Schlusskurs vom Vortag:
$14.48
Offen:
$14.53
24-Stunden-Volumen:
344.92K
Relative Volume:
2.11
Marktkapitalisierung:
$442.25M
Einnahmen:
$66.98M
Nettoeinkommen (Verlust:
$-71.54M
KGV:
-4.7561
EPS:
-3.2043
Netto-Cashflow:
$-18.46M
1W Leistung:
+9.88%
1M Leistung:
+15.02%
6M Leistung:
+41.11%
1J Leistung:
+201.78%
1-Tages-Spanne:
$14.47
$15.28
1-Wochen-Bereich:
$13.57
$15.28
52-Wochen-Spanne:
$4.9604
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Firmenname
Enanta Pharmaceuticals Inc
Sektor
Branche
Telefon
617 607 0800
Adresse
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
15.24 | 420.20M | 66.98M | -71.54M | -18.46M | -3.2043 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2025-10-01 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-08-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Eingeleitet | Evercore ISI | Underperform |
| 2020-08-28 | Fortgesetzt | ROTH Capital | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-23 | Hochstufung | Berenberg | Hold → Buy |
| 2018-12-13 | Eingeleitet | Berenberg | Hold |
| 2018-06-06 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-11 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | Barclays | Underweight |
| 2015-10-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
Alle ansehen
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Progr - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 - BioSpace
Enanta rises as J.P. Morgan starts at Overweight on RSV therapy - MSN
(ENTA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ENTA Price Today: Enanta Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
ENTA (Enanta Pharmaceuticals Inc.) posts 49 percent narrower Q1 2026 loss than expected, shares fall 3.37 percent on slight revenue decline.Management Guidance - Xã Thanh Hà
How (ENTA) Movements Inform Risk Allocation Models - Stock Traders Daily
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
Enanta (ENTA) Begins Phase 1 Trial for EDP-978 - GuruFocus
Enanta doses first patient in phase 1 trial of urticaria drug - Investing.com Australia
Gains Report: Should I trade or invest in Enanta Pharmaceuticals IncEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria - BioSpace
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 in Chronic Urticaria - marketscreener.com
Enanta doses first patient in phase 1 trial of urticaria drug By Investing.com - Investing.com South Africa
Meme Stocks: Does Enanta Pharmaceuticals Inc have strong fundamentals2026 Big Picture & Weekly Setup with High ROI Potential - baoquankhu1.vn
ENTA Stock Price, Quote & Chart | ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) - ChartMill
Are investors bullish on Enanta Pharmaceuticals (ENTA) Stock | ENTA Q4 Earnings: Beats Estimates by $0.40Hedge Fund Inspired Picks - Newser
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 - Business Wire
Is Enanta Pharmaceuticals (ENTA) Stock Suitable for 2026 | Price at $13.18, Up 0.27%Seasonal Patterns - Newser
Trading Systems Reacting to (ENTA) Volatility - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat
Jefferies reiterates Enanta Pharmaceuticals stock rating on patent case By Investing.com - Investing.com Canada
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - BioSpace
Gains Report: Why is Enanta Pharmaceuticals Inc stock going upMarket Growth Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026 - businesswire.com
Enanta (NASDAQ:ENTA) Biotech Momentum Builds Across Nasdaq Index - Kalkine Media
Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Rodman & Renshaw - Defense World
Vanguard disaggregates holdings; reports 0 shares of Enanta (ENTA) - Stock Titan
Enanta Advances Federal Circuit Appeal in Paxlovid Patent Case - TipRanks
Federal Circuit schedules oral argument in Enanta’s patent case against Pfizer - in.investing.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Analysts at Rodman & Renshaw - MarketBeat
Federal Circuit schedules oral argument in Enanta’s patent case against Pfizer By Investing.com - za.investing.com
Aug Catalysts: Can Enanta Pharmaceuticals Inc be recession proofM&A Rumor & Entry Point Confirmation Alerts - baoquankhu1.vn
How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Weekly Recap: How sensitive is Enanta Pharmaceuticals Inc to inflation2026 Movers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Trend Recap: Can Enanta Pharmaceuticals Inc sustain earnings growth2026 Technical Patterns & Smart Allocation Stock Tips - baoquankhu1.vn
ENTA SEC FilingsEnanta Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Free cash flow per share of Enanta Pharmaceuticals, Inc. – FWB:9EP - TradingView
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference - MarketBeat
Commodore Capital LP Buys New Holdings in Enanta Pharmaceuticals, Inc. $ENTA - MarketBeat
Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):